Androgenic Alopecia Clinical Trial
Official title:
Effect of the Composition From Fish on Promoting Hair Growth
Verified date | July 2022 |
Source | Kaohsiung Medical University Chung-Ho Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
According to the World Health Organization data, one out of every five Chinese men has a hair loss symptom, and the hair loss is as high as 84% before the age of 30. Based on the experience of clinicians, there seems to be an increasing trend of alopecia patients who seek the treatment in Taiwan. Treating pathological hair loss requires prompt diagnosis and management to prevent conditions that could lead to permanent hair loss. The current methods of treating hair loss include oral drugs, topical medication, laser illuminating treatment, platelet-rich plasma and hair transplant surgery. However, these treatments also have different disadvantages. Prolonged continuous use of oral and topical medications may be accompanied by side effects. Other treatment modalities may require higher costs, require return visits, or be more invasive. Previous study found that the composition of small DNA fragments (SF DNA) possesses not only toxin-free in primary human skin cells and nude mice, but also inhibits inflammation and ROS generation in the process of skin aging. SF DNA also contributes to promote the proliferation and differentiation of hair follicles, and stimulates the hair growth in nude mice through affecting JAK-STAT pathway. The investigators hypothesize that the clinical application of SF DNA scalp conditioning solution attenuates inflammatory responses, promotes the proliferation and differentiation of hair follicles, and increases the hair of hair loss patients and inspires the quality of life.
Status | Completed |
Enrollment | 53 |
Est. completion date | February 4, 2021 |
Est. primary completion date | February 4, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients within 20~75 years old. - Diagnosed with alopecia by dermatologists. - Willing to maintain the same hair style, color, shampoo and hair products used, and approximate hair length starting from signing ICF and throughout the study. - The subject can understand and obey order. Exclusion Criteria: - Pregnant, nursing, or planning a pregnancy during the study. - Use of any topical medication (such as minoxidil or any other solution for hair growth), laser therapy, or chemotherapy, within the preceding 4 weeks. - Personal medical history of abnormal blood clotting such as bleeding disorders or platelet dysfunction syndrome. - Personal medical history of unstable vital signs such as hypotension or uncontrolled hypertension syndrome. - Prior hair transplant. - Chronic scalp disorders that require medications. - Uses medication known to cause hair thinning such as Coumadin and anti- depressants/anti-psychotics. - Existing scalp diseases such as folliculitis, scalp psoriasis, seborrheic dermatitis, or inflammatory scalp conditions. - Enrolled in any other medical study or has been enrolled in any medical study in the past 6 months. - Any hematologic abnormalities. - Severe allergies manifested by a history of anaphylaxis, or history or presence of multiple severe allergies. - Planned upcoming surgeries. - Tattoo on scalp. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Kaohsiung Municipal Ta-Tung Hospital | Kaohsiung |
Lead Sponsor | Collaborator |
---|---|
Kaohsiung Medical University Chung-Ho Memorial Hospital |
Taiwan,
Hsu WL, Lu JH, Noda M, Wu CY, Liu JD, Sakakibara M, Tsai MH, Yu HS, Lin MW, Huang YB, Yan SJ, Yoshioka T. Derinat Protects Skin against Ultraviolet-B (UVB)-Induced Cellular Damage. Molecules. 2015 Nov 12;20(11):20297-311. doi: 10.3390/molecules201119693. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | hair density | using the hair scalp analysis device to measure hair density at the vertex baldness site. | 4 weeks | |
Other | hair diameter | using the hair scalp analysis device to measure hair diameter at the vertex baldness site. | 4 weeks | |
Other | DLQI questionnaire | Participants answered the DLQI questionnaire by self. Higher scores mean a worse outcome (poor quality of life). | 4 weeks | |
Primary | hair density | using the hair scalp analysis device to measure hair density at the vertex baldness site. | 8 weeks | |
Primary | hair diameter | using the hair scalp analysis device to measure hair diameter at the vertex baldness site. | 8 weeks | |
Secondary | Dermatology Life Quality Index (DLQI) questionnaire | Participants answered the DLQI questionnaire by self. Higher scores mean a worse outcome (poor quality of life). | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06110377 -
MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine)
|
Phase 4 | |
Recruiting |
NCT05611593 -
Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia
|
Phase 1 | |
Completed |
NCT03676400 -
Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia
|
N/A | |
Recruiting |
NCT05938569 -
Computer-Assisted Hair Restoration Study Using ARTAS System
|
N/A | |
Not yet recruiting |
NCT06326359 -
Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
|
N/A | |
Recruiting |
NCT05426629 -
Hydraderm for Androgenic Alopecia
|
Phase 4 | |
Recruiting |
NCT05369481 -
Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia
|
N/A | |
Recruiting |
NCT05827991 -
A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia
|
N/A | |
Not yet recruiting |
NCT06292533 -
Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study
|
N/A | |
Completed |
NCT02824380 -
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia
|
Phase 1 | |
Completed |
NCT06112782 -
Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality
|
N/A | |
Completed |
NCT02594046 -
The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia
|
N/A | |
Recruiting |
NCT05435625 -
Fractional Laser Versus Radiofrequency in Androgenetic Alopecia
|
N/A | |
Completed |
NCT03506503 -
Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia
|
N/A | |
Completed |
NCT03467412 -
To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin
|
Phase 2 | |
Completed |
NCT01852487 -
Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia
|
N/A | |
Not yet recruiting |
NCT03474718 -
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
|
Early Phase 1 | |
Active, not recruiting |
NCT02914587 -
Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study
|
N/A | |
Completed |
NCT04341363 -
Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling
|
N/A | |
Completed |
NCT04450602 -
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
|
N/A |